메디웨일, 국제의료영상처리학회 의료AI 대회서 1위 수상 - 한스경제 https://ift.tt/mGMrUPz

Channel
바이오 뉴우스
@biotherapy777
On this record: Growth · Engagement · Posts · Cite this entry
82subscribers
-1 since we began measuring on 8 August 2026
Risers and fallers across the register · movement among entries of Under 1,000.
Register entry
| Telegram ID | -1001368713590 |
|---|---|
| Type | Channel |
| Username | @biotherapy777 |
| Created | Between 1 March 2018 and 31 August 2021— estimated from Telegram’s id allocation, not measured. How this range is calculated. |
| First recorded | 9 August 2026 |
| Last confirmed live | 23 August 2026 |
| Measurements held | 3 |
| Confirmed unchanged | 1 time, most recently 23 August 2026 |
| On Telegram | t.me/biotherapy777 |
Growth
| Measured (UTC) | Subscribers | Change |
|---|---|---|
| 23 Aug 2026, 19:58 | 82 | -1 |
| 9 Aug 2026, 17:46 | 83 | no change |
| 8 Aug 2026, 02:48 | 83 | first reading |
Engagement
20 posts held, back to 29 October 2024 — the reader has not yet reached the start of this channel’s public history, so older posts may sit further back, unread. Read across 1 pageof Telegram’s post history, 20 posts per page.
Nothing published in the last 30 days. ERR and ER are rolling 30-day measures, so there is nothing to compute — we hold 20 posts for this entry, the most recent from 29 October 2024. An engagement rate over an empty window would be a number about nothing.
Recent posts
노인성 황반변성 주사제 ‘아일리아’…삼성에피스 등 시밀러 약진 - 이코노믹리뷰 https://ift.tt/vlyKbVY
[인터뷰] “치매 신약 레켐비, 두 번 실패 끝 탄생…안전성 우려 해소될 것” - 조선비즈 - 조선비즈 https://ift.tt/RwUTf5V
에자이, 치매 신약 '레켐비' 병용 타우 타깃 'E2814' 2상 개시 - 네이트 뉴스 https://ift.tt/7eqFjgr
에자이, 치매 신약 '레켐비' 병용 타우 타깃 'E2814' 2상 개시 - 네이트 뉴스 https://ift.tt/7eqFjgr
[인터뷰] “치매 신약 레켐비, 두 번 실패 끝 탄생…안전성 우려 해소될 것” - 조선비즈 https://ift.tt/2BlYO5s
코야 테라퓨틱스, 알츠하이머병 임상 2상서 긍정적 결과 - 메디소비자뉴스 https://ift.tt/kDz7Lqx
에자이, 치매 신약 '레켐비' 병용 타우 타깃 'E2814' 2상 개시 - 네이트 뉴스 https://ift.tt/WJBQ9Xk
[인터뷰] “치매 신약 레켐비, 두 번 실패 끝 탄생…안전성 우려 해소될 것” - 조선비즈 - 조선비즈 https://ift.tt/RwUTf5V
에자이, 치매 신약 '레켐비' 병용 타우 타깃 'E2814' 2상 개시 - 네이트 뉴스 https://ift.tt/WJBQ9Xk
코야 테라퓨틱스, 알츠하이머병 임상 2상서 긍정적 결과 - 메디소비자뉴스 https://ift.tt/kDz7Lqx
더블유앤피바이오, ‘뉴클레오스킨’ 국내 독점 총판 - 청년의사 https://ift.tt/yL6JbOi
Showing the 12 most recent of 20 posts we hold for @biotherapy777. View and reaction counts are the latest single reading for each post, not a live figure, and a recent post is still accumulating both. A view count marked ≈ was rounded by Telegram before we ever saw it — t.me prints views in full below 1,000 and to three significant figures above, so ≈1,200,000 means somewhere between 1,150,000 and 1,249,999. Unmarked counts are exact. Text is reproduced from the public post preview and truncated for length.
Cite this entry
A live page changes as we take new readings, so a citation should name the measurement it is based on, not just the URL. The line below cites the subscriber count as measured 23 August 2026 — this entry's latest reading, not the date you are reading this.
“바이오 뉴우스” (@biotherapy777), 82 subscribers as measured 23 August 2026. Telegram Register, tgregister.com/channel/biotherapy777.
Full measurement history, CC BY 4.0. Every reading this register holds for this entry, not just the latest one, as a dated, downloadable record: CSV · JSON. Free to use with attribution to tgregister.com. Each file carries its own generation timestamp, which is the figure to cite for exactly when the data was retrieved.